iCAD (NASDAQ:ICAD) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

iCAD, Inc. (NASDAQ:ICAD) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares changing hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Trading Down 4.9 %

The company’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.61. The stock has a market capitalization of $52.02 million, a P/E ratio of -15.08 and a beta of 1.40.

Hedge Funds Weigh In On iCAD

A hedge fund recently raised its stake in iCAD stock. Perritt Capital Management Inc increased its stake in iCAD, Inc. (NASDAQ:ICAD) by 14.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,900 shares of the technology company’s stock after purchasing an additional 19,917 shares during the period. Perritt Capital Management Inc owned approximately 0.60% of iCAD worth $208,000 as of its most recent SEC filing. 24.61% of the stock is owned by institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.